Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
Retrieved on:
Monday, October 11, 2021
Forward-looking statement, Arrest & Trial, Patient, Inflammation, Cirrhosis, Publication, Hebrew University of Jerusalem, TEL, Eleazar Sukenik, Non-alcoholic fatty liver disease, Liver, COVID-19, SCD, Physician, Manuscript, Drug development, Safety, PK, Population, Annual report, SEC, Kinetics, Terminology, ARMOR, FDA, Steatosis, Perception, Hepatocyte, EMA, Liver cancer, SCD1, AMPK, Hepatic stellate cell, Fatty liver disease, Clinical trial, Cardiovascular disease, Obesity, Risk, NASH, Mall of America, Pharmaceutical industry, Dietary supplement
TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).
Key Points:
- TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).
- The ARREST Phase 2b study randomized 247 patients with NASH confirmed by liver biopsy.
- Data from the ARREST Phase 2b study published in this paper demonstrate how the mechanism of action of Aramchol translates into clinical performance.
- Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.